Funder: National Institutes of Health
Due Dates: June 14, 2025 (New) | July 14, 2025 (Renewal/Resubmission/Revision) | October 17, 2025 (New) | November 17, 2025 (Renewal/Resubmission/Revision)
Funding Amounts: Up to $500,000 direct costs/year (UG3, max 2 years); up to $750,000 direct costs/year (UH3, max 4 years); total project period up to 6 years.
Summary: Supports pragmatic trials to test evidence-based cancer-related interventions across the cancer control continuum, emphasizing health equity and diverse U.S. populations/settings.
Key Information: UG3/UH3 phased cooperative agreement; clinical trial required; milestones must be met for UH3 transition; non-domestic organizations not eligible.
Description
This opportunity from the National Cancer Institute (NCI) aims to accelerate the development and testing of evidence-based cancer-related interventions that address the diversity of people, places, and contexts across the United States. The program specifically supports pragmatic trials—studies designed to evaluate interventions in real-world settings—to improve cancer-related outcomes across the cancer control continuum (prevention, detection, diagnosis, treatment, survivorship, and end-of-life care).
The funding mechanism is a two-phase UG3/UH3 cooperative agreement:
- UG3 phase (up to 2 years): Supports preparatory activities, including piloting and refining the intervention, finalizing study protocols, and establishing partnerships.
- UH3 phase (up to 4 years): Supports the full-scale pragmatic trial, contingent on successful completion of UG3 milestones and NCI approval.
Interventions may include behavioral, technology-mediated, community-based, healthcare delivery, multilevel, or implementation strategies. Projects are encouraged to focus on populations experiencing health disparities and settings with limited resources.
Due Dates
- June 14, 2025: New applications
- July 14, 2025: Renewal, resubmission, and revision applications (as allowed)
- October 17, 2025: New applications
- November 17, 2025: Renewal, resubmission, and revision applications (as allowed)
Letters of intent are requested 30 days prior to the application due date.
Funding Amount
- UG3 Phase: Up to $500,000 in direct costs per year (maximum 2 years)
- UH3 Phase: Up to $750,000 in direct costs per year (maximum 4 years)
- Total Project Period: Up to 6 years (2 years UG3 + 4 years UH3)
- Transition to UH3: Based on achievement of UG3 milestones, administrative review, and NCI approval
The number of awards is contingent on NIH appropriations and the submission of a sufficient number of meritorious applications.
Eligibility
Eligible Applicants:
- U.S.-based:
- Public and private institutions of higher education
- Nonprofits (with or without 501(c)(3) status)
- For-profit organizations (including small businesses)
- State, county, city, township, and special district governments
- Independent school districts
- Public housing authorities/Indian housing authorities
- Native American tribal governments and organizations (federally recognized and other)
- Faith-based and community-based organizations
- Regional organizations
- U.S. territories and possessions
- Eligible agencies of the federal government
Not Eligible:
- Non-domestic (non-U.S.) entities
- Non-domestic components of U.S. organizations
Principal Investigators: Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research.
Application Process
- Submission: Applications must be submitted electronically via Grants.gov, NIH ASSIST, or an institutional system-to-system solution.
- Required Registrations: SAM, eRA Commons, Grants.gov (allow several weeks for completion).
- Letter of Intent: Strongly encouraged, due 30 days before the application deadline.
- Application Format: Follow the NIH SF424 (R&R) Application Guide and the PAR-25-072 instructions.
- Research Strategy: Limited to 25 pages; must address both UG3 and UH3 phases, including milestones and timelines.
- Clinical Trial: Required; must include at least one intervention and one control/comparison condition.
- Data Management and Sharing Plan: Required for all applications.
- Letters of Support: Required from key partners and decision makers.
Additional Information
- Scope: Only pragmatic trials of cancer-related interventions are supported. Applications proposing first-in-human studies, drug/device safety trials, or lacking required milestones are non-responsive.
- Milestones: Clear, quantifiable milestones for both UG3 and UH3 phases are required. Transition to UH3 is not automatic.
- Focus on Health Equity: Projects are encouraged to address health disparities and include diverse populations and settings.
- Review Criteria: Significance, innovation, approach (including rigor and feasibility), investigator(s), and environment. Milestones and plans for inclusion of health disparity populations are critical.
- Data Sharing: Compliance with NIH Data Management and Sharing Policy is required.
External Links
Contact Information
| Area | Name | Email | Phone |
|---|
| Implementation Science | Wynne E. Norton, PhD | wynne.norton@nih.gov | 240-276-6875 |
| Health Disparities & Equity | Amy Kennedy, PhD, MPH | amy.kennedy@nih.gov | 240-781-3335 |
| Health Disparities & Equity | Shobha Srinivasan, PhD | sriniva2@mail.nih.gov | 240-276-6938 |
| Cancer Survivorship | Emily Tonorezos, MD, MPH | Emily.tonorezos@nih.gov | 240-276-5048 |
| Behavioral Research | Frank Perna, EdD, PhD | pernafm@mail.nih.gov | 240-276-6782 |
| Epidemiology & Genomics | Nonniekaye F. Shelburne, CRNP, MS, AOCN | nshelburne@mail.nih.gov | 240-276-6897 |
| Healthcare Delivery | Sarah Kobrin, PhD, MPH | kobrins@mail.nih.gov | 240-276-6931 |
| Grants Info | NIH Grants Information | GrantsInfo@nih.gov | 301-480-7075 |
| Grants Management | Crystal Wolfrey | wolfreyc@mail.nih.gov | 240-276-6277 |
For technical assistance with electronic submission:
- eRA Service Desk | 301-402-7469 or 866-504-9552
See Also